National Stem Cell Holding Announces Patent Application for Newly
Discovered Cellular Derived Biomaterials for Tissue Repair and Wound
Care Applications
MOUNTAINSIDE, N.J., July 25 /PRNewswire-
Stem
Cell Holding, Inc. (OTC: NHGI.PK), together with Michael Cohen and
Jacob
Cohen, today announced the filing of a provisional patent application
for a
newly discovered group of cellular derived biomaterials that appear to
promote tissue repair in a variety of wound care applications. These
new
biomaterials are derived from the company's proprietary stem cell and
progenitor cell lines.
Preclinical studies with these newly discovered biomaterials
appear to
enhance the rate of tissue repair and healing and of the strength of
healed
wounds. The Company believes that further research and development
will
clarify indications thus far that these biomaterials may be useful
for a
wide variety of acute and chronic wounds including but not limited to,
burns, surgery related, and diabetes related.
Government Accounting Office (GAO) statistics show a tremendous
need
for wound care treatment. Each year, according to the GAO,
approximately
five million Americans suffer from chronic wounds caused by diabetes,
circulatory problems and many other conditions. Other relevant
statistics
on wounds include: 1) 1.5 million people who will suffer from chronic
wounds have diabetic ulcers; 2) 2.5 million people have pressure
ulcers; 3)
1 million people have venous stasis (circulatory) ulcers; 4) 15
percent of
all diabetics will develop chronic wounds; 5) Patients with diabetes
have a
15-fold increase in the risk of amputation; 6) Approximately 60,000
diabetics will undergo amputation each year and wound care has grown
to
become a $2 billion market globally. National Stem Cell's work
provides for
wounds to heal faster and stronger.
National Stem Cell Holding, Inc. is a biotechnology company
focused on
developing therapeutics based upon the use of human cells and their
derivatives. The Company is developing a pipeline of proprietary stem
cell
therapeutics with particular focus on diabetes. In addition to its
work
with stem cell therapeutics, the Company is also working to leverage
its
commercial infrastructure and product development capabilities of its
wholly-owned subsidiary The Sperm Bank of NY. The Company's
investigational
products are focused on the improvement of the quality of life for
patients
and their families. The Company is headquartered in Mountainside, NJ.
Except for the historical information contained herein, the
matters set
forth in this press release are forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995, as amended. Forward-looking statements
are
statements that are not historical facts. Words such as "expect(s),"
"feel(s)," "believe(s),
expressions are intended to identify forward-looking statements, which
include, but are not limited to statements regarding: the trademark
application, the ability of the biomaterials to promote tissue repair
and
the variety of wound care applications. All of such forward-looking
statements are not guarantees of future performance. They are based on
management's current expectations and are subject to risks and
uncertainties that are difficult to predict and generally beyond the
control of the Company, and that could cause actual results to differ
materially from those expressed in, or implied or projected by, the
forward-looking information and statements. These risks and
uncertainties
include, but are not limited to: the risk that the patent application
will
not be granted, the risk that the analysis of future data will not
warrant
continuation of development; the risk that the FDA, the institutional
review boards for the clinical sites or the investigators may not
agree
with the Company's assessment of the results and may not permit future
trials; the risk that concerns may arise from additional analysis or
data;
and the risk that the Company may encounter other unexpected hurdles.
Readers are cautioned not to place undue reliance on these forward-
looking statements that speak only as of the date hereof. National
Stem Cell Holding, Inc. does not undertake any obligation to update
or revise any forward-looking statements, to reflect changes to
management's expectations, change in events, conditions or
circumstances after the date hereof, or the occurrence of or non-
occurrence of any events, new information or otherwise.
SOURCE National Stem Cell Holding, Inc.
http://www.prnewswi
ACCT=104&STORY=
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
